Alexion Pharmaceuticals Inc (ALXN)

126.65
0.81 0.64
NASDAQ : Health Care
Prev Close 127.46
Open 126.77
Day Low/High 125.39 / 127.81
52 Wk Low/High 110.56 / 205.29
Volume 1.33M
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 224.02M
Market Cap 28.18B
EPS 0.70
P/E Ratio 199.68
Div & Yield N.A. (N.A)

Latest News

Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital

Alexion Pharmaceuticals (ALXN) Stock Gets ‘Outperform’ Rating at RBC Capital

Alexion Pharmaceuticals (ALXN) stock was initiated with an "outperform" rating at RBC Captial earlier today as the firm expects the company 'to continue to dominate the rare disease space.'

Alexion Pharmaceuticals To Report Second Quarter 2016 Results On Thursday, July 28, 2016

Alexion Pharmaceuticals To Report Second Quarter 2016 Results On Thursday, July 28, 2016

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2016 on Thursday, July 28, 2016 before the US financial markets open.

Alexion (ALXN) Stock Gains on Ratings Upgrade

Alexion (ALXN) Stock Gains on Ratings Upgrade

Alexion (ALXN) stock is increasing in pre-market trading after Credit Suisse upped its rating to 'outperform' given its upside potential.

Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More

Analysts' Actions -- Baker Hughes, ConocoPhillips, GameStop, Toll Brothers and More

Here are Monday's top research calls, including an upgrade for GameStop, and downgrades for Baker Hughes, ConocoPhillips and Toll Brothers.

New Data From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) Presented At ICNMD Annual Congress

New Data From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG) Presented At ICNMD Annual Congress

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers presented new results from the REGAIN study, a global, placebo-controlled Phase 3 registration trial of eculizumab (Soliris ®) in patients...

The 10 Worst-Performing S&P 500 Stocks in June

The 10 Worst-Performing S&P 500 Stocks in June

Brexit volatility put a major damper on the global markets this month, and investors who owned these 10 S&P 500 stocks saw their profits shrink substantially in June.

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

Biotech Stock Mailbag: Mid-Year Assessment, Where We Go From Here

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

The Brexit-related market pullback has created stock-buying opportunities. Here are 14 more stocks for investors to consider from Morgan Stanley.

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

RBC sees biopharma 'insulated' from Brexit, says buy Celgene for bounceback

The U.S. woke up today to the news of a "Brexit" win, which has sent global markets reeling.

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

Biotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Late-Breaking Data Presented At EHA: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase 1/2 Study Exhibit Rapid And Sustained Reductions In LDH

Late-Breaking Data Presented At EHA: All Patients With PNH Treated With Once-Monthly Dosing Of ALXN1210 In Phase 1/2 Study Exhibit Rapid And Sustained Reductions In LDH

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that interim data were presented from a Phase 1/2 study of ALXN1210, an investigational, highly innovative longer-acting anti-C5 antibody, in patients with...

Rev's Forum: Don't Be Seduced by the Market's Dark Side

Too many turn bearish too quickly just because they can't find any entry points.

Trader's Daily Notebook: Gusher for Oil Stocks

Big move for biotechs isn't pleasant.

Here’s Why Shares of Biogen and Alexion Tanked On Tuesday

Here’s Why Shares of Biogen and Alexion Tanked On Tuesday

Shares of Biogen and Alexion Pharmaceuticals took a hit Tuesday after their promising new products failed clinical trials.

Trending Tickers: Z, VRX, BIIB, ALXN

U.S. indices are up as oil continues its climb past $50 a barrel.

Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Unusual Social Activity Stock

Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Unusual Social Activity Stock

Trade-Ideas LLC identified Alexion Pharmaceuticals (ALXN) as an unusual social activity candidate

Alexion Pharmaceuticals (ALXN) Lags In Post-Market Trading

Alexion Pharmaceuticals (ALXN) Lags In Post-Market Trading

Trade-Ideas LLC identified Alexion Pharmaceuticals (ALXN) as a post-market laggard candidate

Alexion Announces Topline Results From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Announces Topline Results From Phase 3 REGAIN Study Of Eculizumab (Soliris®) In Patients With Refractory Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab (Soliris ®) in patients with refractory generalized myasthenia gravis (gMG).

European Commission Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

European Commission Grants Orphan Drug Designation To ALXN1210 For The Treatment Of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to ALXN1210, a highly innovative, longer-acting C5 antibody being evaluated in patients with...

Alexion To Present At Upcoming Investor Conferences

Alexion To Present At Upcoming Investor Conferences

Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) today announced that management will present at two upcoming investor conferences: Goldman Sachs 37 th Annual Healthcare Conference in Rancho Palos Verdes on Wednesday,...

Alexion Pharmaceuticals Becomes #156 Most Shorted S&P 500 Component, Replacing WEC Energy Group

Alexion Pharmaceuticals Becomes #156 Most Shorted S&P 500 Component, Replacing WEC Energy Group

The most recent short interest data has been released for the 05/13/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

'Mad Money' Lightning Round: I'm Flying With Delta

'Mad Money' Lightning Round: I'm Flying With Delta

Cramer says he has liked Taser for ages but thinks Sarepta Therapeutics is a battleground stock.

Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today

Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today

Even chatter of a Federal Reserve interest rate hike didn't push stocks down, Cramer says.